Cost effectiveness of child pneumococcal conjugate vaccination in middle-income countries

Mari M. Nakamura, Azadeh Tasslimi, Tracy A. Lieu, Orin Levine, Maria Deloria Knoll, Louise B. Russell, Anushua Sinha

Research output: Contribution to journalArticle

Abstract

Policy-makers require information on the potential benefits of and economic case for pneumococcal conjugate vaccination in middle-income countries. We built decision analysis models to evaluate a three-dose infant series of the 7-, 10- or 13-valent pneumococcal conjugate vaccines in 77 middle-income countries compared with no vaccination, accounting for direct protection of vaccinated children as well as herd protection and serotype replacement in unvaccinated children and adults. Over 10 years, pneumococcal vaccination would prevent at least 11.0 million cases and 314. 000 deaths in children under-5, one-third of the pneumonia and invasive disease cases and deaths that would occur in this age group without vaccination. Herd protection would prevent 3.1 million cases and 163. 000 deaths in older children and adults. A total of 11.1 million discounted disability-adjusted life-years (DALY) would be averted. At a dose cost of $10 for lower- middle-income and $20 for upper-middle-income countries, the net pooled (for all countries together) discounted vaccination cost would be $18.1 billion ($1600 per DALY averted). Vaccination would be cost effective for 72 countries with the 7-valent vaccine and for all countries with the 10- or 13-valent vaccines. The economic case for vaccination is compelling for middle-income countries.

Original languageEnglish (US)
Pages (from-to)270-281
Number of pages12
JournalInternational Health
Volume3
Issue number4
DOIs
StatePublished - Dec 2011

Fingerprint

vaccination
Cost-Benefit Analysis
Vaccination
income
costs
Quality-Adjusted Life Years
death
Costs and Cost Analysis
Vaccines
disability
Economics
Conjugate Vaccines
Decision Support Techniques
model analysis
Administrative Personnel
economics
age group
Pneumonia
infant
Age Groups

Keywords

  • Cost-effectiveness analysis
  • Decision analysis
  • Middle-income countries
  • Seven-valent pneumococcal conjugate vaccine
  • Ten-valent pneumococcal conjugate vaccine
  • Thirteen-valent pneumococcal conjugate vaccine

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Health(social science)

Cite this

Nakamura, M. M., Tasslimi, A., Lieu, T. A., Levine, O., Knoll, M. D., Russell, L. B., & Sinha, A. (2011). Cost effectiveness of child pneumococcal conjugate vaccination in middle-income countries. International Health, 3(4), 270-281. https://doi.org/10.1016/j.inhe.2011.08.004

Cost effectiveness of child pneumococcal conjugate vaccination in middle-income countries. / Nakamura, Mari M.; Tasslimi, Azadeh; Lieu, Tracy A.; Levine, Orin; Knoll, Maria Deloria; Russell, Louise B.; Sinha, Anushua.

In: International Health, Vol. 3, No. 4, 12.2011, p. 270-281.

Research output: Contribution to journalArticle

Nakamura, MM, Tasslimi, A, Lieu, TA, Levine, O, Knoll, MD, Russell, LB & Sinha, A 2011, 'Cost effectiveness of child pneumococcal conjugate vaccination in middle-income countries', International Health, vol. 3, no. 4, pp. 270-281. https://doi.org/10.1016/j.inhe.2011.08.004
Nakamura, Mari M. ; Tasslimi, Azadeh ; Lieu, Tracy A. ; Levine, Orin ; Knoll, Maria Deloria ; Russell, Louise B. ; Sinha, Anushua. / Cost effectiveness of child pneumococcal conjugate vaccination in middle-income countries. In: International Health. 2011 ; Vol. 3, No. 4. pp. 270-281.
@article{81932d2378524940a5526c7527b24f48,
title = "Cost effectiveness of child pneumococcal conjugate vaccination in middle-income countries",
abstract = "Policy-makers require information on the potential benefits of and economic case for pneumococcal conjugate vaccination in middle-income countries. We built decision analysis models to evaluate a three-dose infant series of the 7-, 10- or 13-valent pneumococcal conjugate vaccines in 77 middle-income countries compared with no vaccination, accounting for direct protection of vaccinated children as well as herd protection and serotype replacement in unvaccinated children and adults. Over 10 years, pneumococcal vaccination would prevent at least 11.0 million cases and 314. 000 deaths in children under-5, one-third of the pneumonia and invasive disease cases and deaths that would occur in this age group without vaccination. Herd protection would prevent 3.1 million cases and 163. 000 deaths in older children and adults. A total of 11.1 million discounted disability-adjusted life-years (DALY) would be averted. At a dose cost of $10 for lower- middle-income and $20 for upper-middle-income countries, the net pooled (for all countries together) discounted vaccination cost would be $18.1 billion ($1600 per DALY averted). Vaccination would be cost effective for 72 countries with the 7-valent vaccine and for all countries with the 10- or 13-valent vaccines. The economic case for vaccination is compelling for middle-income countries.",
keywords = "Cost-effectiveness analysis, Decision analysis, Middle-income countries, Seven-valent pneumococcal conjugate vaccine, Ten-valent pneumococcal conjugate vaccine, Thirteen-valent pneumococcal conjugate vaccine",
author = "Nakamura, {Mari M.} and Azadeh Tasslimi and Lieu, {Tracy A.} and Orin Levine and Knoll, {Maria Deloria} and Russell, {Louise B.} and Anushua Sinha",
year = "2011",
month = "12",
doi = "10.1016/j.inhe.2011.08.004",
language = "English (US)",
volume = "3",
pages = "270--281",
journal = "International Health",
issn = "1876-3413",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Cost effectiveness of child pneumococcal conjugate vaccination in middle-income countries

AU - Nakamura, Mari M.

AU - Tasslimi, Azadeh

AU - Lieu, Tracy A.

AU - Levine, Orin

AU - Knoll, Maria Deloria

AU - Russell, Louise B.

AU - Sinha, Anushua

PY - 2011/12

Y1 - 2011/12

N2 - Policy-makers require information on the potential benefits of and economic case for pneumococcal conjugate vaccination in middle-income countries. We built decision analysis models to evaluate a three-dose infant series of the 7-, 10- or 13-valent pneumococcal conjugate vaccines in 77 middle-income countries compared with no vaccination, accounting for direct protection of vaccinated children as well as herd protection and serotype replacement in unvaccinated children and adults. Over 10 years, pneumococcal vaccination would prevent at least 11.0 million cases and 314. 000 deaths in children under-5, one-third of the pneumonia and invasive disease cases and deaths that would occur in this age group without vaccination. Herd protection would prevent 3.1 million cases and 163. 000 deaths in older children and adults. A total of 11.1 million discounted disability-adjusted life-years (DALY) would be averted. At a dose cost of $10 for lower- middle-income and $20 for upper-middle-income countries, the net pooled (for all countries together) discounted vaccination cost would be $18.1 billion ($1600 per DALY averted). Vaccination would be cost effective for 72 countries with the 7-valent vaccine and for all countries with the 10- or 13-valent vaccines. The economic case for vaccination is compelling for middle-income countries.

AB - Policy-makers require information on the potential benefits of and economic case for pneumococcal conjugate vaccination in middle-income countries. We built decision analysis models to evaluate a three-dose infant series of the 7-, 10- or 13-valent pneumococcal conjugate vaccines in 77 middle-income countries compared with no vaccination, accounting for direct protection of vaccinated children as well as herd protection and serotype replacement in unvaccinated children and adults. Over 10 years, pneumococcal vaccination would prevent at least 11.0 million cases and 314. 000 deaths in children under-5, one-third of the pneumonia and invasive disease cases and deaths that would occur in this age group without vaccination. Herd protection would prevent 3.1 million cases and 163. 000 deaths in older children and adults. A total of 11.1 million discounted disability-adjusted life-years (DALY) would be averted. At a dose cost of $10 for lower- middle-income and $20 for upper-middle-income countries, the net pooled (for all countries together) discounted vaccination cost would be $18.1 billion ($1600 per DALY averted). Vaccination would be cost effective for 72 countries with the 7-valent vaccine and for all countries with the 10- or 13-valent vaccines. The economic case for vaccination is compelling for middle-income countries.

KW - Cost-effectiveness analysis

KW - Decision analysis

KW - Middle-income countries

KW - Seven-valent pneumococcal conjugate vaccine

KW - Ten-valent pneumococcal conjugate vaccine

KW - Thirteen-valent pneumococcal conjugate vaccine

UR - http://www.scopus.com/inward/record.url?scp=84855981268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855981268&partnerID=8YFLogxK

U2 - 10.1016/j.inhe.2011.08.004

DO - 10.1016/j.inhe.2011.08.004

M3 - Article

C2 - 24038500

AN - SCOPUS:84855981268

VL - 3

SP - 270

EP - 281

JO - International Health

JF - International Health

SN - 1876-3413

IS - 4

ER -